Results 321 to 330 of about 356,633 (356)
Some of the next articles are maybe not open access.
Pathophysiology of Acute Myeloid Leukemia
Acta Haematologica<b><i>Background:</i></b> Acute myeloid leukemia (AML) is a biologically heterogenous disease arising in clonally proliferating hematopoietic stem cells. Sequential acquisition of mutations leads to expanded proliferation of clonal myeloid progenitors and failure of differentiation, leading to fulminant AML.
Franziska, Wachter, Yana, Pikman
openaire +2 more sources
Immunophenotyping of Acute Myeloid Leukemia
2019Immunophenotyping by multiparameter flow cytometry is a rapid and efficient technique to simultaneously assess and correlate multiple individual cell properties like size and internal complexity along with antigen expression in a population of cells. This method is utilized for rapid characterization of the blasts and classification of acute myeloid ...
Pallavi Kanwar, Galera +2 more
openaire +2 more sources
Angiogenesis in acute myeloid leukemia
Blood, 2000We have read with interest the report of Padro et al[1][1] showing an increased angiogenesis in acute myeloid leukemia. Recently, other studies published in Blood also have shown that angiogenesis in acute myeloid leukemias is higher than in controls[2][2] and that it has an independent ...
DI RAIMONDO, FRANCESCO +3 more
openaire +3 more sources
Acute Myeloid Leukemia in the Elderly
Seminars in Oncology, 2008The incidence of acute myeloid leukemia (AML) is increasing with age. As the results associated with standard intensive chemotherapy remain particularly disappointing in older patients, they represent an ideal target population for clinical and therapeutic investigations.
Hervé, Dombret +2 more
openaire +2 more sources
Childhood Acute Myeloid Leukemia
Current Treatment Options in Oncology, 2008Despite the use of intensive chemotherapy and hematopoietic stem cell transplantation, approximately one-third of children with acute myeloid leukemia (AML) still suffer relapse of their disease. It is unlikely that improvements in outcome can be achieved by further intensification of conventional chemotherapy.
openaire +2 more sources
Cytogenetics in acute myeloid leukemia
Current Oncology Reports, 2002Cytogenetic analysis is the most important diagnostic tool for determining prognosis in acute myeloid leukemia (AML). In the majority of patients with AML, acquired clonal chromosome aberrations can be observed. Numerous recurrent karyotype abnormalities have been discovered in AML.
Claudia, Schoch, Torsten, Haferlach
openaire +2 more sources
Mayo Clinic Proceedings, 2006
Acute myeloid leukemia (AML) is a group of several different diseases, the treatment and outcome of which depend on several factors, including leukemia karyotype, patient age, and comorbid conditions. Despite advances in understanding the molecular biology of AML, its treatment remains challenging.
Elias J, Jabbour +2 more
openaire +2 more sources
Acute myeloid leukemia (AML) is a group of several different diseases, the treatment and outcome of which depend on several factors, including leukemia karyotype, patient age, and comorbid conditions. Despite advances in understanding the molecular biology of AML, its treatment remains challenging.
Elias J, Jabbour +2 more
openaire +2 more sources
Immunohistochemistry in Acute Myeloid Leukemia
2017The World Health Organization's Classification of Tumours of Haematopoietic and Lymphoid Tissues (Swerdlow et al. (eds) WHO Classification of tumours of haematopoietic and lymphoid tissues, 4th edn. WHO Press, Lyon, 2008) created a classification scheme incorporating genetic, molecular, morphologic, and immunophenotypic characteristics.
openaire +2 more sources
New England Journal of Medicine, 1999
Löwenberg, Bob, Downing, JR, Burnett, A
openaire +3 more sources
Löwenberg, Bob, Downing, JR, Burnett, A
openaire +3 more sources
Decitabine for acute myeloid leukemia
Expert Review of Anticancer Therapy, 2012Decitabine (Dacogen(®), Eisai Inc., NJ, USA) is a nucleoside analogue DNA methyltransferase inhibitor first synthesized and documented to have antileukemic efficacy over 40 years ago. Over the years, the dosing of decitabine has been refined, such that for acute myeloid leukemia, a 5-day schedule of 20 mg/m(2) is now commonly utilized.
openaire +2 more sources